Publicaciones en colaboración con investigadores/as de Duke University (7)

2021

  1. Corrigendum to “Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions. [European Neuropsychopharmacology Volume 48, July 2021, Pages 3-31]” (European Neuropsychopharmacology (2021) 48 (3–31), (S0924977X2100239X), (10.1016/j.euroneuro.2021.05.010))

    European Neuropsychopharmacology

  2. Drug development for Autism Spectrum Disorder (ASD): Progress, challenges, and future directions

    European Neuropsychopharmacology, Vol. 48, pp. 3-31

2018

  1. Variance of IQ is partially dependent on deletion type among 1,427 22q11.2 deletion syndrome subjects

    American Journal of Medical Genetics, Part A, Vol. 176, Núm. 10, pp. 2172-2181

2015

  1. Cognitive decline preceding the onset of psychosis in patients with 22q11.2 deletion syndrome

    JAMA Psychiatry, Vol. 72, Núm. 4, pp. 377-385

2014

  1. Synaptic, transcriptional and chromatin genes disrupted in autism

    Nature, Vol. 515, Núm. 7526, pp. 209-215

2013

  1. Cognition in schizophrenia: Summary nice consultation meeting 2012

    European Neuropsychopharmacology

  2. Issues and perspectives in designing clinical trials for negative symptoms in schizophrenia

    Schizophrenia Research, Vol. 150, Núm. 2-3, pp. 328-333